Table 3.
Mean proportion of statistically significant effect sizes by the scheme
| Schemes | Proportion of significant effect sizes | Number of effect sizes | Number of studies |
|---|---|---|---|
| aAfghanistan P4P | 0 | 7 | 1 |
| CAPI-ROSP | 0.82 | 37 | 3 |
| aChronic disease P4P | 0.20 | 35 | 1 |
| aCommunity-based psychiatric care P4P | 1 | 6 | 1 |
| aHighmark’s Quality Blue (QB) in Pennsylvania | 1 | 1 | 1 |
| aImprove hospital discharge follow-ups P4P | 0 | 5 | 1 |
| aMedicaid | 0.18 | 28 | 1 |
| aMental health P4P | 1 | 24 | 1 |
| aP4P for Antibiotics | 0.50 | 6 | 1 |
| P4P for Diabetes | 0.74 | 98 | 9 |
| P4P for Hepatitis | 0.75 | 8 | 2 |
| aP4P for Immunization | 0.36 | 28 | 1 |
| P4P for Malaria | 0.82 | 11 | 1 |
| aP4P for Maternal care | 0.73 | 67 | 3 |
| aP4P for drug prescription | 0.50 | 24 | 1 |
| aPartners for Kids | 0.67 | 21 | 1 |
| aPay for results P4P | 0.60 | 63 | 1 |
| aPhysician Integrated Network (PIN) | 0.67 | 3 | 1 |
| Quality and Outcomes Framework | 0.33 | 6 | 2 |
| aQueensland P4P | 0.25 | 4 | 1 |
| Rwanda P4P | 0.19 | 108 | 1 |
| aSpontaneous breathing (SBTs) P4P | 0.50 | 18 | 1 |
| aLow-Density lipoprotein Cholesterol (LDL-C) | 0.33 | 12 | 1 |
Note: a denotes the new schemes evaluated in the new studies